A meta-analysis of 32 randomized trials with 2,783 participants found GLP-1 receptor agonists resolved fatty liver inflammation 3.3 times more often than controls and reduced liver fat by 4.3%, while DPP-4 inhibitors only lowered blood sugar.
RR 3.33 for MASH resolutionGLP-1 receptor agonists resolved steatohepatitis without worsening fibrosis over three times more often than controls across 32 randomized trials with 2,783 participants
What the researchers found
Across 32 randomized controlled trials with 2,783 participants, GLP-1 receptor agonists were associated with resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis at a relative risk of 3.33 (95% CI 2.38–4.66, I²=12.9%), demonstrating remarkable consistency across studies.
GLP-1 RAs reduced liver fat content by a weighted mean difference of -4.34% (95% CI -5.88 to -2.81), though with high heterogeneity (I²=95.3%). They also significantly improved liver function tests, serum triglycerides, body weight, BMI, waist circumference, and HbA1c. Gastrointestinal side effects were increased.
DPP-4 inhibitors showed no significant effects on any liver or metabolic parameter except HbA1c (WMD -0.62%, 95% CI -0.91 to -0.33), establishing a clear distinction between the two incretin-based drug classes for liver disease.
Why it matters
MASLD/MAFLD is the most common liver disease worldwide, affecting roughly a quarter of the global population, and can progress to cirrhosis and liver cancer. Until recently, no pharmacological treatment was approved for it. This comprehensive meta-analysis of 32 RCTs provides strong evidence that GLP-1 receptor agonists not only improve liver fat and inflammation but can actually resolve steatohepatitis — the dangerous inflammatory stage — without worsening fibrosis. This supports GLP-1 drugs as a promising treatment for a disease with enormous global burden.
How the study worked
Systematic review and meta-analysis following standard methodology, searching PubMed, Cochrane Library, and EMBASE for studies published before December 2024. Included 32 randomized controlled trials with 2,783 participants with MASLD. Outcomes included liver histology, liver fat content, liver function, serum lipids, anthropometric measures, HbA1c, and gastrointestinal side effects. Results were pooled using relative risk for categorical outcomes and weighted mean differences for continuous outcomes, with heterogeneity assessed by I².
What this study cannot tell us
High heterogeneity (I²=95.3%) in the liver fat content analysis suggests substantial variability across trials in study design, patient populations, specific drugs used, and treatment durations. The meta-analysis groups different GLP-1 RAs together (including single, dual, and triple agonists), which may obscure differences between individual drugs. Most trials were relatively short-term, and long-term outcomes (cirrhosis prevention, liver cancer risk) remain unknown. The increased gastrointestinal side effects may limit tolerability for some patients.
How to read the evidence
This is a systematic review and meta-analysis of 32 randomized controlled trials — high-quality evidence. The low heterogeneity for the primary histological outcome (I²=12.9%) is particularly reassuring, though the high heterogeneity for liver fat content suggests variability in secondary outcomes. The large number of included RCTs and clear separation between GLP-1 RA and DPP-4 inhibitor effects strengthen the conclusions.
When this study was published
Published in 2025 with literature search through December 2024, this is a very current meta-analysis capturing the latest RCT evidence on incretin therapies for fatty liver disease. The timing aligns with rapid clinical interest in GLP-1 drugs for liver indications.
The bigger picture
The approval of resmetirom (a thyroid hormone receptor agonist) as the first drug for MASH in 2024 opened the door, but GLP-1 receptor agonists may offer broader metabolic benefits since they also address obesity, diabetes, and cardiovascular risk — all common comorbidities in MASLD patients. This meta-analysis builds the evidence case for GLP-1 RAs as a multi-target therapy for the metabolic syndrome that underlies fatty liver disease.
Questions still open
- Which specific GLP-1 receptor agonist is most effective for MASLD — and do dual or triple agonists like tirzepatide offer greater liver benefits?
- Can GLP-1 drugs not only resolve steatohepatitis but also reverse existing liver fibrosis with longer treatment?
- For patients with both type 2 diabetes and fatty liver disease, should GLP-1 receptor agonists now be considered first-line therapy?
Common questions
Can GLP-1 drugs cure fatty liver disease?
Why don't DPP-4 inhibitors help the liver if they also work on the incretin system?
Read the original research
Efficacy of Incretin-Based Therapies in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal of gastroenterology and hepatology, 40(11), 2659-2673
Citation
Liu, Lili; Xia, Ying; Wang, Bian; Zhang, Yiyu. (2025). Efficacy of Incretin-Based Therapies in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Journal of gastroenterology and hepatology, 40(11), 2659-2673. https://doi.org/10.1111/jgh.70084